Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease

Regulatory Peptides

Volumn 163, Issue 1-3, 2010, Pages 137-142

  Yamagata, Bun ^a   Watanabe, Takuya ^a   Tomioka, Hiroi ^a   Kobayashi, Hitomi ^a   Nakano, Yasuko ^b   Mimura, Masaru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cognitive function; Donepezil; Insulin like growth factor I; Responder

Indexed keywords

BIOLOGICAL MARKER; DONEPEZIL; SOMATOMEDIN C;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; JAPANESE; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDANS; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; PIPERIDINES;

EID: 77953916898     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.04.010     Document Type: Article

References (29)

1. Arai H. Pharmacotherapy for Alzheimer-type dementia and acetylcholine-pharmacological effects of donepezil. Jpn J Clin Psychopharmacol 2000, 3:1001-1008.
2. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998, 8:67-75.
3. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Möller H.J., et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999, 10:237-244.
4. Whitehead A., Perdomo C., Pratt R.D., Birks J., Wilcock G.K., Evans J.G. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease a meta-analysis of individual patient data from randomized controlled trials. Am J Geriatr Psychiatry 2004, 19:624-633.
5. Doody R.S., Geldmacher D.S., Gordon B., Perdomo C.A., Pratt R.D. Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001, 58:427-433.
6. Black S.E., Doody R., Li H., McRae T., Jambor K.M., Xu Y., et al. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology 2007, 69:459-469.
7. Feldman H., Gauthier S., Hecker J., Jambor K.M., Xu Y., Sun Y., et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trail. Int J Geriatr Psychiatry 2005, 20:559-569.
8. Winblad B., Kilander L., Eriksson S., Minthon L., Båtsman S., Wetterholm A.L., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367:1057-1065.
9. Mega M.S., Masterman D.M., O'Connor S.M., Barclay T.R., Cummings J.L. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999, 56:1388-1393.
10. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disord 2000, 14(suppl 1):S3-10.
11. Nozawa M., Ichimiya Y., Nozawa E., Utumi Y., Sugiyama H., Murayama N., et al. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics 2009, 9:50-55.
12. Dik M.G., Pluijm S.M., Jonker C., Deeg D.J., Lomecky M.Z., Lips P. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging 2003, 24:573-581.
13. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490:127-133.
14. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer Dis 2005, 8:247-268.
15. Watanabe T., Miyazaki A., Katagiri T., Yamamoto H., Idei T., Iguchi T. Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J Am Geriatr Soc 2005, 53:1748-1753.
16. Tei E., Yamamoto H., Watanabe T., Miyazaki A., Nakadate T., Kato N., et al. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. Growth Horm IGF Res 2008, 18:47-54.
17. Folstein M., Folstein S., McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
18. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br J Psychiatr 1982, 140:566-572.
19. Watanabe T., Itokawa T., Nakagawa Y., Iguchi T., Katagiri T. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003, 16:754-760.
20. Sanz C., Andrieu S., Sinclair A., Hanaire H., Vellas B. REAL.FR Study Group. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 2009, 73:1359-1366.
21. Li N.C., Lee A., Whitmer R.A., Kivipelto M., Lawler E., Kazis L.E., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465.
22. Fonseca AC, Resende R, Oliveira CR, Pereira CM. Cholesterol and statins in Alzheimer's disease: Current controversies. Exp Neurol 2010;223:282-93.
23. Arwert L.I., Deijen J.B., Drent M.L. The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis. Growth Horm IGF Res 2005, 15:416-422.
24. Paolisso G., Ammendola S., Del Buono A., Gambardella A., Riondino M., Tagliamonte M.R., et al. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centanarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab 1997, 82:2204-2209.
25. Okereke O., Kang J.H., Ma J., Hankinson S.E., Pollak M.N., Grodstein F. Plasma IGF-1 levels and cognitive performance in older women. Neurobiol Aging 2007, 28:135-142.
26. Landi F., Capoluongo E., Russo A., Onder G., Cesari M., Lulli P., et al. Free insulin-like growth factor-I and cognitive function in older persons living in community. Growth Horm IGF Res 2007, 17:58-66.
27. Obermayr R.P., Mayerhofer L., Knechtelsdorfer M., Mersich N., Huber E.R., Geyer G., et al. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. Exp Gerontol 2005, 40:157-163.
28. Narimatsu N., Harada N., Kurihara H., Nakagata N., Sobue K., Okajima K. Donepezil improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. J Pharmacol Exp Ther 2009, 330:2-12.
29. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 2009, 6:213-223.